ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Review

Dysmenorrhea and related disorders

[version 1; peer review: 3 approved]
PUBLISHED 05 Sep 2017
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

Dysmenorrhea is a common symptom secondary to various gynecological disorders, but it is also represented in most women as a primary form of disease. Pain associated with dysmenorrhea is caused by hypersecretion of prostaglandins and an increased uterine contractility. The primary dysmenorrhea is quite frequent in young women and remains with a good prognosis, even though it is associated with low quality of life. The secondary forms of dysmenorrhea are associated with endometriosis and adenomyosis and may represent the key symptom. The diagnosis is suspected on the basis of the clinical history and the physical examination and can be confirmed by ultrasound, which is very useful to exclude some secondary causes of dysmenorrhea, such as endometriosis and adenomyosis. The treatment options include non-steroidal anti-inflammatory drugs alone or combined with oral contraceptives or progestins.

Keywords

Dysmenorrhea, endometriosis, adenomyosis, menstrual disorders

Introduction

Dysmenorrhea is defined as the presence of painful cramps of uterine origin that occur during menstruation and represents one of the most common causes of pelvic pain and menstrual disorder. The International Association for the Study of Pain defines pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage”1. In particular, chronic pelvic pain is located in the pelvic area and lasts for 6 months or longer2.

The burden of dysmenorrhea is greater than any other gynecological complaint3: dysmenorrhea is the leading cause of gynecological morbidity in women of reproductive age regardless of age, nationality, and economic status47. The effects extend beyond individual women to society, resulting annually in an important loss of productivity8,9. Thus, the World Health Organization estimated that dysmenorrhea is the most important cause of chronic pelvic pain10.

The estimated prevalence of dysmenorrhea is high, although it varies widely, ranging from 45 to 93% of women of reproductive age3,10, and the highest rates are reported in adolescents11,12. Because it is accepted as a normal aspect of the menstrual cycle and therefore is tolerated, women do not report it13 and do not seek medical care13,14. Some women (3 to 33%) have very severe pain, severe enough to render them incapacitated for 1 to 3 days each menstrual cycle, requiring absence from school or work15,16. Indeed, dysmenorrhea has a high impact on women’s lives, resulting in a restriction of daily activities17,18, a lower academic performance in adolescents19,20, and poor quality of sleep21, and has negative effects on mood, causing anxiety and depression22.

Definition and pathogenesis

On the basis of pathophysiology, dysmenorrhea is classified as primary dysmenorrhea (menstrual pain without organic disease) or secondary dysmenorrhea (menstrual pain associated with underlying pelvic pathology)23. The cause of primary dysmenorrhea is not well established. However, the responsible cause has been identified on the hyper-production of uterine prostaglandins, particularly of PGF2a and PGF2, thus resulting in increased uterine tone and high-amplitude contractions24. Women with dysmenorrhea have higher levels of prostaglandins, which are highest during the first two days of menses25. Prostaglandin production is controlled by progesterone: when progesterone levels drop, immediately prior to menstruation, prostaglandin levels increase13,24. If the exposure of endometrium to luteal phase is crucial for the increased production of progesterone, dysmenorrhea occurs only with ovulatory cycles. This could explain why primary dysmenorrhea onset is shortly after menarche and why dysmenorrhea responds well to ovulatory inhibition. However, multiple other factors may play a role in the perception and the severity of pain, which does not depend only on endocrine factors26.

The recurrent menstrual pain is associated with central sensitization, which is associated with structural and functional modification of the central nervous system24,27. Given that dysmenorrhea might led to important long-term consequences and may be increasing women’s susceptibility to others chronic pain conditions later in life, it is mandatory to treat menstrual pain in order to limit the noxious input into the central nervous system24. The most common causes of secondary dysmenorrhea in young women are endometriosis and adenomyosis.

Endometriosis

Endometriosis is characterized by the presence of endometrial tissue (glands and stroma) outside the uterine cavity and is the most common cause of secondary dysmenorrhea27,28. Pain symptoms negatively influence physical and psychological well-being of women with endometriosis. All forms of pain induce elevated sympathetic nervous system activity and this is considered a stressor, inducing changes in neuromediators, neuroendocrine, and hormonal secretions27,29.

Given that women with endometriosis wait before getting the right diagnosis30, a great deal of effort has been made in recent years to try to find signs and symptoms that would help in making an earlier diagnosis. The early identification of these symptoms could help reduce the delay necessary for diagnosis15 and enable the use of less invasive procedures31. An early age onset of dysmenorrhea is considered a risk factor for endometriosis32; other menstrual characteristics such as cycle length and menstrual bleeding duration and quantity are not related to the development of endometriosis. Parameters that may predict a later finding of deep infiltrating endometriosis are prolonged use of oral contraceptives (OCs) for treating primary dysmenorrhea, absenteeism from school during menstruation, and a positive family history of dysmenorrhea33.

The endometriosis prevalence is higher in adolescents with chronic pelvic pain resistant to treatment with OC pills and non-steroidal anti-inflammatory drugs (NSAIDs) and in girls with dysmenorrhea34. Therefore, severe dysmenorrhea that does not respond to medical therapy warrants further investigation such as by laparoscopy35.

Adenomyosis

Adenomyosis is defined as the presence of endometrial glands and stroma within the myometrium and is associated with dysmenorrhea and abnormal uterine bleeding (AUB). Adenomyosis is one of the most common causes of AUB36. The diagnosis is usually confirmed through transvaginal ultrasonography and magnetic resonance imaging. Via specific ultrasonographic criteria by bidimensional and tridimensional transvaginal ultrasound (morphological uterus sonographic assessment)37, the detection of adenomyosis features by imaging is accepted and the association with menstrual pain, heavy menstrual bleeding, and infertility may facilitate the diagnosis of adenomyosis38. A 34% incidence of adenomyosis ultrasonographic features is found in young nulligravid women 18 to 30 years of age and is associated with dysmenorrhea39.

Risk factors

Heavy menstrual bleeding and longer menstrual bleeding duration are often associated with dysmenorrhea3,20. Childbearing is a very influential factor for the decrease of dysmenorrhea5. Increasing age is also associated with less severe dysmenorrhea12, although a longitudinal study found that the proportion of women with moderate to severe dysmenorrhea remained constant with increasing age5.

The early onset of pain is associated with more severe pain3, and a family history of dysmenorrhea is associated with a significantly higher prevalence of dysmenorrhea20. Since anxiety and depression are often associated, dysmenorrhea may be part of a somatoform syndrome3.

Diagnosis

A focused history and physical examination are usually sufficient for making a diagnosis of primary dysmenorrhea23,26. The onset of primary dysmenorrhea is usually 6 to 12 months after menarche. The typical pain is sharp and intermittent, is located in the suprapubic area, and develops within hours of the start of menstruation and peaks with maximum blood flow23. The physical examination is completely normal, and the menstrual pain may be associated with systemic symptoms, such as nausea, vomiting, diarrhea, fatigue, fever, headache, and insomnia11,16,40. There is no evidence for routine use of ultrasound in the evaluation of primary dysmenorrhea, although ultrasound is very useful in excluding the secondary causes of dysmenorrhea, such as endometriosis and adenomyosis26 (Figure 1).

Dysmenorrhea that occurs any time after menarche, that is associated with other gynecological symptoms such as dyspareunia, heavy menstrual bleeding, AUB, and infertility, and that does not respond to treatment with NSAIDs or OCs might be suspicious for secondary dysmenorrhea23,24. In particular, the analysis of menstrual bleeding abnormalities associated with dysmenorrhea might be helpful for the diagnosis of adenomyosis (Figure 1).

78bbb5dc-7989-46a9-9283-ea2fd6a93d9d_figure1.gif

Figure 1. Flowchart for the management of patients with dysmenorrhea.

Flowchart for the management of patients with dysmenorrhea.

Treatment

The aim of the treatment for primary dysmenorrhea is pain relief.

Non-steroidal anti-inflammatory drugs

NSAIDs are usually the first-line therapy for dysmenorrhea and should be tried for at least three menstrual periods41,42. If NSAIDs alone are not sufficient, OCs can be combined with it. NSAIDs are drugs that act by blocking prostaglandin production through the inhibition of cyclooxygenase, an enzyme responsible for formation of prostaglandins. Common NSAIDs (aspirin, naproxen, and ibuprofen) are very effective in reliving period pain43. They make the menstrual cramps less severe and can prevent other symptoms such as nausea and diarrhea44. NSAIDs reduce moderate to severe pain in women with primary dysmenorrhea23. With the widespread availability of NSAIDs, the management of dysmenorrhea is mainly self-care13,18.

Oral contraceptives

Contraceptive hormones act by suppressing ovulation and causing no endometrial proliferation13. OCs bring almost immediate relief from symptoms associated with menstruation: heavy periods, painful periods, and irregular bleeding. In addition, OCs often are used as therapeutic drugs for women with symptomatic menorrhagia or endometriosis45,46.

The effectiveness of OC therapy for treating dysmenorrhea, regardless of the administration route (oral, transdermal, intravaginal, or intrauterine), has been shown12,4651. The use of OCs in a continuous fashion can be considered to treat primary dysmenorrhea, with two main advantages: the reduction of associated menstrual disorders and the improvement in women’s pain relief26. However, limited evidence supports the use of OCs as a standard treatment23.

The choice between the use of combined OCs and oral progesterone should be guided by the patient’s pain relief, the toleration of possible adverse effects especially linked to the frequency of breakthrough bleeding and weight gain, and the patient’s basal risk of venous thromboembolism52.

Progestins

Hormonal progestins-only treatment produces a benefit on menstrual pain, causing endometrial atrophy and inhibiting ovulation. Several long-acting reversible progestin contraceptives have been found to be effective treatments for primary dysmenorrhea. These include 52-mg (20 µg/day) levonorgestrel-releasing intaruterine system, the etonogestrel-releasing subdermal implant, and depot medroxyprogesterone53.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 05 Sep 2017
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Bernardi M, Lazzeri L, Perelli F et al. Dysmenorrhea and related disorders [version 1; peer review: 3 approved] F1000Research 2017, 6(F1000 Faculty Rev):1645 (https://doi.org/10.12688/f1000research.11682.1)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 05 Sep 2017
Views
0
Cite
Reviewer Report 05 Sep 2017
Caio Parente Barbosa, Collective Health Department, Division of Sexual and Reproductive Health Care and Population Genetics, Faculty of Medicine ABC, Santo André, Brazil 
Approved
VIEWS 0
I confirm that I have read this submission and believe that I have an ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Barbosa CP. Reviewer Report For: Dysmenorrhea and related disorders [version 1; peer review: 3 approved]. F1000Research 2017, 6(F1000 Faculty Rev):1645 (https://doi.org/10.5256/f1000research.12620.r25214)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
0
Cite
Reviewer Report 05 Sep 2017
Juan Luis Alcázar, Department of Obstetrics and Gynecology, University of Navarra, School of Medicine, Pamplona, Spain 
Approved
VIEWS 0
I confirm that I have read this submission and believe that I have an ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Alcázar JL. Reviewer Report For: Dysmenorrhea and related disorders [version 1; peer review: 3 approved]. F1000Research 2017, 6(F1000 Faculty Rev):1645 (https://doi.org/10.5256/f1000research.12620.r25215)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
0
Cite
Reviewer Report 05 Sep 2017
Luis Bahamondes, Department of Obstetrics and Gynecology, Universidade Estadual de Campinas, Campinas, Brazil 
Approved
VIEWS 0
I confirm that I have read this submission and believe that I have an ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Bahamondes L. Reviewer Report For: Dysmenorrhea and related disorders [version 1; peer review: 3 approved]. F1000Research 2017, 6(F1000 Faculty Rev):1645 (https://doi.org/10.5256/f1000research.12620.r25213)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 05 Sep 2017
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.